Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.32 |
| ▸ | APP | P05067 | 3/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17215450 | 0.88 | OPRM1 (0.36) | — | |
| SCHEMBL17367483 | 0.86 | ACHE (0.31) | LPAR1 | |
| SCHEMBL17367475 | 0.79 | PTK2 (0.40) | PTGS1APPCYP2C9CYP2C19CYP3A4 | |
| SCHEMBL17367468 | 0.79 | SLC6A3 (0.35) | APPLPAR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL17367476 | 0.78 | MAPT (0.35) | PTGS1APPCYP2C9CYP2C19CYP3A4 | |
| SCHEMBL22271721 | 0.77 | APP (0.44) | APPCYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL17216091 | 0.75 | OPRM1 (0.38) | — | |
| SCHEMBL17371010 | 0.74 | OPRM1 (0.40) | — | |
| SCHEMBL17367472 | 0.73 | AAK1 (0.37) | — | |
| SCHEMBL17367478 | 0.73 | ALDH1A1 (0.42) | PTGS1APPCYP2C9CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150376160-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376160-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | LPAR3, LPAR1, LPAR2 | PTGS1 2492/4885APP 4316/4885LPAR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.